Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | EYENOVIA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
Do | Eyenovia, Inc.: Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq | 78 | GlobeNewswire (Europe) | Combination, if successful, would create a new publicly-listed eye care company combining Betaliq's EyeSol® water-free drug delivery technology for glaucoma with Eyenovia's Optejet® device platform... ► Artikel lesen | |
EYENOVIA Aktie jetzt für 0€ handeln | |||||
05.03. | EYENOVIA, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
26.02. | Eyenovia regains compliance with Nasdaq | 1 | Seeking Alpha | ||
26.02. | Eyenovia regains Nasdaq compliance, eyes strategic options | 1 | Investing.com | ||
24.02. | Eyenovia defers debt payments to bolster liquidity | 2 | Investing.com | ||
24.02. | EYENOVIA, INC. - 8-K, Current Report | - | SEC Filings | ||
24.02. | Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives | 93 | GlobeNewswire (Europe) | NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet®... ► Artikel lesen | |
06.02. | Wainwright maintains neutral Eyenovia stock, $2 target | 4 | Investing.com | ||
05.02. | Eyenovia, Inc.: Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device | 2 | GlobeNewswire (USA) | ||
31.01. | EYENOVIA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
28.01. | Eyenovia approves 1-for-80 reverse stock split; shares slip | 4 | Seeking Alpha | ||
28.01. | Eyenovia, Inc.: Eyenovia Announces 1-for-80 Reverse Stock Split | 155 | GlobeNewswire (Europe) | NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet... ► Artikel lesen | |
24.01. | EYENOVIA, INC. - 8-K, Current Report | 4 | SEC Filings | ||
16.01. | EYENOVIA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
15.01. | Eyenovia, Inc.: Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote "FOR" Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders | 7 | GlobeNewswire (USA) | ||
10.01. | Deal Dispatch: TD Bank To Sell Charles Schwab Stake? Eyenovia, Smart Share Hit Auction Block | 3 | Benzinga.com | ||
06.01. | Eyenovia explores strategic alternatives, advances Optejet device | 3 | Investing.com | ||
06.01. | Eyenovia, Inc.: Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives | 1 | GlobeNewswire (USA) | ||
30.12.24 | EYENOVIA, INC. - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
INNOCAN PHARMA | 0,127 | +2,83 % | Innocan Pharma Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
CRESCO LABS | 0,650 | +1,01 % | Cresco Labs has price target chopped at Roth | ||
CSPC PHARMA | 0,602 | -0,53 % | CSPC Pharmaceutical Group-Aktie heute am Aktienmarkt kaum gefragt: Kurs fällt (0,5726 €) | Im Wertpapierhandel notiert die CSPC Pharmaceutical Group-Aktie derzeit ein wenig leichter. Der jüngste Kurs betrug 0,57 Euro. Die CSPC Pharmaceutical Group-Aktie verzeichnet aktuell einen Abschlag... ► Artikel lesen | |
TONIX PHARMACEUTICALS | 18,260 | 0,00 % | Tonix Pharmaceuticals Holding: As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread | Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within families and among children, whereas the 2022 Clade II mpox - still spreading... ► Artikel lesen | |
AMARIN | 0,420 | +3,96 % | Amarin Corporation plc: New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor ... | DUBLIN and BRIDGEWATER, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will... ► Artikel lesen | |
NEWRON PHARMACEUTICALS | 9,260 | -0,43 % | Newron Pharmaceuticals S.p.A.: Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference | Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous system... ► Artikel lesen | |
NEKTAR THERAPEUTICS | 0,807 | +1,90 % | NEKTAR THERAPEUTICS - S-8, Securities to be offered to employees in employee benefit plans | ||
COMPASS PATHWAYS | 2,820 | +2,92 % | Compass Pathways plc: Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression | Highlights: 52-week observational follow-up study from Phase 2b reveals single 25 mg COMP360 psilocybin dose offers longer-term antidepressant effects compared to lower doses, with average... ► Artikel lesen | |
JAGUAR HEALTH | 0,251 | 0,00 % | Jaguar Health, Inc. Announces Reverse Stock Split | Reverse split approved at March 2025 Special Meeting of StockholdersShares of Jaguar Health common stock to begin trading on split-adjusted basis on March 24, 2025 SAN FRANCISCO, CA / ACCESS Newswire... ► Artikel lesen | |
XORTX THERAPEUTICS | 0,968 | +3,86 % | XORTX gibt Update zu Gesprächen mit der FDA bekannt | - Gespräche im Rahmen eines Typ-B-Meetings für ein verkürztes NDA-Zulassungsverfahren für XRx-026 zur Gichtbehandlung
CALGARY, ALBERTA, den 19. März 2025 / IRW-Press / XORTX... ► Artikel lesen | |
NUMINUS WELLNESS | 0,027 | -100,00 % | Numinus Wellness Inc: Numinus gets state nod for therapy training program | ||
CANNOVUM CANNABIS | 0,208 | -18,75 % | EQS-News: Cannovum Cannabis AG: Abwicklung bzw. Veräußerung der Beteiligungen im Cannabis-Bereich | EQS-News: Cannovum Cannabis AG
/ Schlagwort(e): Strategische Unternehmensentscheidung/Sonstiges
Cannovum Cannabis AG: Abwicklung bzw. Veräußerung der Beteiligungen im Cannabis-Bereich... ► Artikel lesen | |
TALPHERA | 0,549 | 0,00 % | Talphera, Inc.: Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study | Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week
The FDA agreed to... ► Artikel lesen | |
OPUS GENETICS | 1,056 | +2,33 % | Opus Genetics, Inc.: Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., March 19, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the... ► Artikel lesen | |
BETTERLIFE PHARMA | 0,049 | +1,03 % | BETTERLIFE HLDG (06909): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 20 MARCH 2025 |